Evolent Health Inc. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.